润都股份(002923.SZ)：获得沙库巴曲缬沙坦钠片药品注册证书

Core Viewpoint - Rundu Co., Ltd. has received two drug registration certificates from the National Medical Products Administration for Sacubitril/Valsartan tablets, marking a significant milestone as the first ARNI approved globally for heart failure treatment [1] Group 1: Product Approval - The approved Sacubitril/Valsartan tablets are indicated for adult patients with reduced ejection fraction chronic heart failure (NYHA II-IV, LVEF ≤ 40%) [1] - This medication is designed to reduce the risk of cardiovascular death and hospitalization due to heart failure [1] - It can replace ACE inhibitors or ARBs and can be used in combination with other heart failure treatments [1] Group 2: Therapeutic Benefits - Sacubitril/Valsartan demonstrates superior blood pressure-lowering effects compared to standard antihypertensive medications [1] - The drug is also applicable for the treatment of primary hypertension [1]